Navigation Links
CLEANSEQ DYE-TERMINATOR REMOVAL

CleanSEQ is a SPRI-based dye-terminator removal system with a simple, three-step protocol requiring no centrifugation or filtration steps. CleanSEQ produces superior quality sequencing results and is easily automated, making it the preferred dye-terminator removal method in many of the top genomic research facilities.

HIGH QUALITY SEQUENCING RESULTS

CleanSEQ consistently delivers:

  • Long Phred20 read lengths
  • Increased fluorescent signal strength
  • Efficient elimination of unincorporated dyes (Figure 1)

  • FLEXIBLE PURIFICATION
    CleanSEQ is compatible with common sequencing chemistries and platforms in both 96 and 384-well formats.

    PLATFORMS:
  • ABI Prism 3730, 3700 and 3100
  • Beckman CEQ
  • Amersham MegaBACE

    REAGENTS:
  • BigDye versions 1.0, 1.1, 2.0, 3.0 and 3.1
  • DYEnamic ET
  • CEQ DTCS



    COMPLETE CLEANSEQ AUTOMATION
    The lack of centrifugation and filtration steps allows CleanSEQ protocols to be completely automated while maintaining superior performance. CleanSEQ is fully compatible with most commonly used low, medium and high throughput liquid handling systems. Contact Agencourt for the most up-to-date list of supported platforms.



    CleanSEQ has been successfully automated on the Biomek FX from Beckman Coulter in 96 and 384-well formats. (Photo courtesy of Beckman Coulter.)




    '"/>


  • Source:


    Page: All 1

    Related biology technology :

    1. COSMCPREP HIGH AND LOW COPY PLASMID PURIFICATION
    2. SPRINTPREP SINGLE STEP PLASMID PURIFICATION
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: CLEANSEQ DYE TERMINATOR REMOVAL

    (Date:7/31/2014)... famous for a number of breakthroughs, which altered the ... a paper, which laid the foundation of computer science, ... He next played a pivotal role in the Second ... military codes, enabling the Allies to defeat the Nazis ... he turned his attention to artificial intelligence and proposed ...
    (Date:7/31/2014)... , July 31, 2014 The ... today with $25,000 to fund a translational research ... in 2011, the gift was presented at the ... Annual Meeting in Colorado Springs, CO. ... in neurointerventional approaches to neurovascular conditions, SNIS formed ...
    (Date:7/31/2014)... North Shore Towers, a luxury co-op community based just ... of the nation’s leading combined heating and power (CHP) systems ... CHP system. The original CHP system had been maintained since ... life of the plant, GI Energy was contracted to replace ... equipment, while maintaining continuous operation of the entire complex. ...
    (Date:7/31/2014)... DIEGO, July 31, 2014 Senomyx ... leading company using proprietary taste science technologies to ... the food, beverage, and ingredient supply industries, today ...  The Company ended the second quarter with $33.6 ... "During the past quarter Senomyx achieved ...
    Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
    ... Nov. 21, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), an ... the three and nine months ended September 30, 2011 ... adoption of its SmartChip System. "During the ... strategy to address the rapidly changing needs of the ...
    ... Phase I Single Dose Study Data ... Convergence Pharmaceuticals Limited ("Convergence"), the company focused ... medicines, today announces that the multiple ascending dose Phase ... channel blocker CNV2197944, for the treatment of chronic pain ...
    ... Japan, November 18, 2011 - A research group from ... and Fujitsu Limited today announced that research results obtained ... Bell Prize, Peak-Performance at SC11, the International Conference for ... in Seattle, on November 17 (US Pacific Standard Time). ...
    Cached Biology Technology:WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 2WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 3WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 4WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 5WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 6WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 7WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy 8Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 2Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 3Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 4'K computer' research results awarded ACM Gordon Bell Prize 2
    (Date:8/1/2014)... Modern humans appear in the fossil record about 200,000 ... ago that making art and advanced tools became widespread. ... the journal Current Anthropology finds that human ... testosterone levels at around the same time that culture ... innovation, making art and rapid cultural exchange probably came ...
    (Date:8/1/2014)... examining a taxonomically confused group of marine mammals ... the Australian humpback dolphin, Sousa sahulensis , ... Enterprises. , The study describing the newly ... long systematic examination of all available historical records, ... widespread group of coastal cetaceans ranging from the ...
    (Date:8/1/2014)... key component of phloem, the conductive tissue through which ... molecules. Elongated cylindrical cells are capped at one end ... sieve tubes which in turn form a network throughout ... very special cells which play an important role in ... known about their differentiation," says Professor Yk Helariutta from ...
    Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3Developmental regulation of important plant phloem components discovered 2
    ... indicating that more than 50% of all osteoporotic hip fractures ... and treatment of osteoporotic fractures has become a major health ... Osteoporosis (IOF WCO), to be held for the first time ... the region to attend the leading global congress devoted to ...
    ... new drug trabectedin with pegylated liposomal doxorubicin provides clinical ... new results presented at the 33rd Congress of the ... The combination, which importantly does not include a ... women whose cancer recurs at least 6 months after ...
    ... N.C. A newly discovered chemical pathway that helps ... 20 common beta-blockers, drugs that are prescribed to millions ... Researchers from Duke University Medical Center tested 20 beta ... and carvedilol -- could stimulate a pathway recently found ...
    Cached Biology News:IOF World Congress on Osteoporosis in Bangkok to address Asian issues 2Promising new treatment option for women with recurrent ovarian cancer 22 beta blockers found to also protect heart tissue 2
    Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
    SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
    Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
    All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
    Biology Products: